NCT02191254已完成3 期
A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 245
- 主要终点
- Change from baseline in limb volume determination
研究概览
简要总结
Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •18 years of age or older
- •CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification
- •Willing and able to give written informed consent prior to participation in the study
排除标准
- •Concomitant diseases:
- •Decompensated cardiac insufficiency
- •Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
- •Peripheral arterial disease (ankle/arm pressure index < 0.9)
- •Current acute phlebitis or thrombosis
- •Renal insufficiency (serum creatinine > 1.5 mg/dl)
- •Liver disease (SGPT > 3x upper limit of normal)
- •Other diseases: hyper- or hypocalcaemia, malignancies
- •Anamnestic indications of diabetic microangiopathy or polyneuropathy
- •Drug and/or alcohol abuse
- •Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- •Immobility
- •Avalvulia
- •Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- •State after pulmonary embolism
- •Recognised hypersensitivity to the trial drug ingredients
- •Current florid venous ulcus
- •Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.
- •Previous treatments:
- •Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures
- •Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
- •Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication
- •Concomitant treatment/non-drug therapy exclusion criteria:
- •Other venous drugs apart from the trial medication
- •Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
- •Extensive use of laxatives
- •Major surgery requiring full anaesthesia
- •Other exclusion criteria:
- •Previously studied under this protocol
- •Participation in another clinical trial within the previous 90 days or during the present study
- •Patient is investigator, co-investigator, or study nurse in this study
- •Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- •Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- •Patients in a bad general health state according to the investigator's judgement
研究组 & 干预措施
Antistax®
Experimental
1 tablet per day for 12 weeks
干预措施: Antistax® (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in limb volume determination
时间窗: Baseline, day 84
water displacement method
次要结局
- Global assessment of tolerability by the patient on a 4-point VRS(day 84)
- Number of patients with adverse events(up to 12 weeks)
- Changes in limb volume determination(Baseline, day 21 and day 42)
- Changes in the calf circumference(Baseline, at day 21, 42 and 84)
- Changes in the ankle circumference(Baseline, at day 21, 42, and 84)
- Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)(Baseline, at day 21, 42, and 84)
- Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)(day 84)
- Global assessment of efficacy by the investigator on a 4-point VRS(day 84)
- Global assessment of tolerability by the investigator on a 4-point VRS(Day 84)
- Number of patients with clinically significant changes in laboratory values(Baseline, week 12)
- Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))(Baseline, up to 12 weeks)
研究者
相似试验
已完成
3 期
Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous InsufficiencyVenous InsufficiencyNCT00855179Boehringer Ingelheim250
已完成
4 期
Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)Venous InsufficiencyNCT02184234Boehringer Ingelheim65
已完成
2 期
Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous InsufficiencyVenous InsufficiencyNCT02191163Boehringer Ingelheim71
已完成
3 期
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)Venous InsufficiencyNCT00292435Boehringer Ingelheim202
招募中
3 期
Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral InfectionsAcute Respiratory InfectionNCT06379542Valenta Pharm JSC252